Breast Health

A recently published study evaluated nearly 30,000 patients and found about 5% of Black and White women have the same genetic mutations that are associated with an increased risk of breast cancer.

Disparities across the globe continue to surface as we approach year 2 of the COVID-19 pandemic, especially in health care. As one considers its implications, a research team from the American Cancer Society investigated its potential impact on early cancer detection.

A recent study suggests that unconscious or implicit bias may exist when it comes to physicians referring African American patients with breast cancer for genetic counseling and testing.

Paul Lawrence Baron, MD, discussed best practices for determining a patient’s risk of developing breast cancer, the significance of targeting HER2 in patients with early-stage and metastatic disease, and remaining questions with radiation therapy in the field.

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.

Sara Hurvitz, MD, discusses the coopERA study and how these data, along with findings from other clinical trials, could lead to significant changes in treatment for patients with ER-positive/HER2-negative breast cancer.

Preclinical data shows this investigational vaccine’s potential in preventing triple-negative breast cancer and inhibiting existing tumor growth.

Medically underserved and minority breast cancer survivors experienced improved outcomes and quality of life after participating in community-based physical activity programs, according to recent study results.

They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.

As we move beyond COVID-19, the healthcare industry is just beginning to uncover the impact of delayed cancer screenings and care on oncology outcomes.

The FDA has approved the Ki-67 IHC MIB-1 pharmDx test to assist in determining which patients with early breast cancer who are at high risk of disease recurrence might benefit from adjuvant treatment with abemaciclib plus endocrine therapy.

In honor of October 13 as National Metastatic Breast Cancer Awareness Day, Contemporary OB/GYN® has collected its top metastatic breast cancer articles over the past year.

The FDA has approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of 20% or higher, as determined by an FDA-approved test.

Analyzing the relationship between data from patient self-reports and clinician ratings of vulvovaginal tissue health following cancer can help provide better sexual function treatment for patients, according to a recent study.

Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.

The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.

The overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.

In an interview with Targeted Oncology, Melissa K. Frey, MD, discussed findings from implementing web-based health information collection of family history in patients with gynecologic cancers.

The Major Histocompatibility Complex Class II protein has potential to predict immunotherapy benefit in two types of breast cancer.

Pregnant women who had cancer previously or currently have cancer were more likely to experience comorbidities and in-hospital complications, depending on cancer type.

According to data from the Centers for Disease Control’s (CDC) National Breast and Cervical Cancer Early Detection Program, the total number of cancer screening tests declined 87% for breast cancer and 84% for cervical cancer during April 2020.

The unmet need for personalized follow-up care due to a wide variety of health burdens after treatment needs to be addressed.

Significant updates occurred in women’s health issues while the world was in survival mode.

Missing just 1 screening can lead to significant increase in risk, investigators say.

In honor of International Women’s Day, CURE® compiled some recent news and updates in cancer research that you may have missed.